Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 15, 2016, regarding events occurring on June 14, 2016. The report details the results of the Company's 2016 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals at the annual meeting. As of the record date (April 18, 2016), there were 42,565,019 shares of Class A common stock and 17,524,596 shares of Class B common stock outstanding.
- Proposal 1 (Election of Directors): Stockholders elected three Class I director nominees (David Farner, Michael Kirshbaum, and Norman Payson, MD) for a three-year term. All nominees received majority support.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Proposal 3 (Charter Amendment): Stockholders approved an amendment to the Company's amended and restated certificate of incorporation to remove Section 11.03, the litigation costs provision.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the effective date of the Second Amended and Restated Certificate of Incorporation (Exhibit 3.1) filed on June 14, 2016.
- Confirm the removal of the litigation costs provision (Section 11.03) from the Company's charter.
- Review the definitive proxy statement on Schedule 14A (filed April 28, 2016) for detailed biographies of the newly elected directors and further context on the charter amendment.